Remimazolam (CNS 7056): an
Emerging Sedative and General
Anaesthetic
Published: March 1, 2018 | DOI: https://doi.org/10.7860/JCDR/2018/30823.11263
Sumit Bansal, Shubha Singhal
1. Senior Resident, Department of Anaesthesia, All India Institute of Medical Sciences, New Delhi, India.
2. Senior Resident, Department of Pharmacology, Maulana Azad Medical College (MAMC), New Delhi, India.
Correspondence
Dr. Shubha Singhal,
Senior Resident, Department of Pharmacology, Maulana Azad Medical College (MAMC), New Delhi, India.
E-mail: drshubhasinghal@gmail.com
Remimazolam is a newer drug in the field of anaesthesia. It combines the properties of midazolam and remifentanil. As the name indicates, midazolam is the parent compound of remimazolam which incorporates the pharmacokinetic properties of remifentanil. Remimazolam is an ultra short acting anaesthetic agent/sedative which rapidly shows its effect after injection and also wears off expeditiously after cessation. Therefore, remimazolam’s dosage can be ideally controlled. Since it acts on benzodiazepine receptors, availability of specific antagonist (flumazenil) further adds to its safety in case of overdose.
[
FULL TEXT ] | [ PDF]